The outgrowth of B2M-mutant tumour cell clones represents a manifestation of cancer immunoediting concept10–12 and further supports high immunogenicity of MSI CRCs and their active immune surveillance.13 However, the mechanisms of lymphocyte recruitment that may contribute to the pronounced immune infiltration of MSI cancers have not yet been determined. The gene discussed is B2M; the disease is neoplasm.